Experimental cell therapy for tough leukemia shows early promise but trial halted

NCT ID NCT05886491

Terminated Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new cell therapy called GDX012 in 16 people with acute myeloid leukemia (AML) that had come back or not responded to standard treatment. The main goals were to check safety, find the best dose, and see if the therapy could control the cancer. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Comprehensive Cancer Center of Northwestern University

Chicago, Illinois, 60611, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
National Cancer Center Hospital East

Kashiwa, 277-8577, Japan
Sarah Cannon/CBCI

Denver, Colorado, 80218, United States
Thomas Jefferson University

New York, New York, 10065, United States
Tri-Star BMT/Sarah Cannon Nashville

Nashville, Tennessee, 37203, United States
University of Alabama at Birmingham (UAB) Hospital

Birmingham, Alabama, 35205, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.